Key Points
- Tempus AI CEO Ryan Fukushima sold 23,818 shares at an average price of $46.19, generating approximately $1.10 million. The sale, conducted under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 14.2% to 143,945 shares.
- Tempus AI reported quarterly revenue of $382.49 million, up 21.6% year over year, and an adjusted loss of $0.04 per share, beating analysts’ expectations for a $0.14 loss.
- The stock opened at $46.70, well below its 12-month high of $104.32. Analysts’ consensus rating is Hold, with an average price target of $64.92, although ratings range from Buy to Sell.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director David Epstein sold 370 shares of Tempus AI stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $43.40, for a total value of $16,058.00. Following the completion of the transaction, the director owned 31,094 shares of the company's stock, valued at approximately $1,349,479.60. The trade was a 1.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Stock Down 0.7%
Shares of Tempus AI stock opened at $46.70 on Thursday. The stock has a market capitalization of $8.39 billion, a price-to-earnings ratio of -32.43 and a beta of 3.58. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The business's 50 day simple moving average is $51.40 and its 200-day simple moving average is $52.12.
Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm's revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.22) EPS. Equities research analysts forecast that Tempus AI, Inc. will post -1.35 earnings per share for the current year.
Analysts Set New Price Targets
TEM has been the topic of several recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Friday, July 31st. Jefferies Financial Group assumed coverage on Tempus AI in a research report on Monday, April 13th. They set an "underperform" rating and a $35.00 price objective for the company. Wall Street Zen upgraded Tempus AI from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. TD Cowen reaffirmed a "buy" rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Wolfe Research assumed coverage on Tempus AI in a research report on Tuesday, June 2nd. They set a "peer perform" rating for the company. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Tempus AI currently has a consensus rating of "Hold" and an average price target of $64.92.
View Our Latest Research Report on Tempus AI
Hedge Funds Weigh In On Tempus AI
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GC Wealth Management RIA LLC acquired a new position in shares of Tempus AI in the 4th quarter worth approximately $399,267,000. Voloridge Investment Management LLC lifted its stake in Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock valued at $129,708,000 after purchasing an additional 1,039,176 shares during the last quarter. AQR Capital Management LLC bought a new stake in Tempus AI during the second quarter worth approximately $54,020,000. Amova Asset Management Americas Inc. grew its position in Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company's stock worth $195,549,000 after buying an additional 821,490 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company's stock valued at $195,636,000 after buying an additional 821,490 shares in the last quarter. 24.22% of the stock is owned by institutional investors.
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
